Opinion|Videos|May 1, 2024
New Therapeutic Frontiers in PAH
Author(s)Ronald Oudiz, MD, FACP, FACC, FCCP
A cardiovascular specialist provides an overview of emerging therapies and targets in the PAH treatment space and how they address current unmet needs.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What new therapeutic options have emerged in the pulmonary arterial hypertension (PAH) treatment landscape, and what are their mechanisms of action and potential benefits?
- How do emerging therapies address the unmet needs in PAH management, such as improving symptom control, slowing disease progression, or targeting specific pathways?
Advertisement
Related to this article
Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Among the therapeutic alternatives used in Medicare’s drug price negotiations, many were generics or biosimilars, and most differed in mechanistic class from the negotiated drug.
Why artificial intelligence in health care falls short today and how implementing technology in health care requires integrated workflows to cut costs and improve outcomes.
Experts say no inhaler suits every patient with chronic obstructive pulmonary disease, and technique can fade within 30 days without retraining.
Experts say COPD care should aim for disease stability, with advanced therapy a routine next step, not a last resort, for patients who fall short.
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
The EEOC is reportedly preparing to narrow Pregnant Workers Fairness Act rules; no revised rule has been published as of yet.
Advertisement
Advertisement
Trending on AJMC
1
EEOC Reportedly Plans to Narrow Pregnancy Accommodation Rules
2
How the GOLD 2026 Guidelines Updated COPD Diagnosis and Treatment
3
CF, Bronchiectasis Antimicrobial Resistance Varies Widely by Region
4
2027 GOLD COPD Report Updates: Àlvar Agustí, MD, PhD
5